Commercial StrategyUTHR's established commercial footprint, longstanding relationships with key physicians/target prescribers, and proactive contracting efforts/favorable positioning with payers should help mitigate potential competitive pressures for the Tyvaso franchise.
Growth PotentialThere is still meaningful growth potential for the Tyvaso franchise in PH-ILD, which should continue to support the base business, with longer-term upside potential from IPF.
Therapeutic SynergyUTHR offers a whole solution of prostacyclin (IV, SC, nebulizer, DPI, oral) for PAH patients, creating therapeutic synergy when patients need to switch modalities.